Patent application number | Description | Published |
20090326192 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 12-31-2009 |
20100092496 | CHEMICAL LINKERS AND CONJUGATES THEREOF - The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them. | 04-15-2010 |
20100113476 | CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF - The present disclosure provides drug-ligand conjugates that are potent cytotoxins and include a linker between the drug and ligand where the linker has a single amino acid. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them. | 05-06-2010 |
20110144303 | Biologically Active Peptidomimetic Macrocycles - The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 06-16-2011 |
20110223149 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles with improved properties, such as protease resistance, relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 09-15-2011 |
20130023646 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 01-24-2013 |
20130123169 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease. | 05-16-2013 |
20130210743 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 08-15-2013 |
20130210745 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES - Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 08-15-2013 |
20130274205 | PEPTIDOMIMETIC MACROCYCLES - Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 10-17-2013 |
20140323701 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 10-30-2014 |
20140378390 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 12-25-2014 |
20150051155 | PEPTIDOMIMETIC MACROCYCLES - Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein. These sequences can bind to the MDM2 and/or MDMX proteins. Also provided herein are methods of using such macrocycles for the treatment of diseases and disorders, such as cancers or other disorders characterized by a low level or low activity of a p53 protein or high level of activity of a MDM2 and/or MDMX protein. | 02-19-2015 |